163 related articles for article (PubMed ID: 25316611)
1. Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; Wang L; Sun W; Zhou Y; King J; Kaura S; Zhang A; Yuan P
J Oncol Pharm Pract; 2016 Apr; 22(2):205-11. PubMed ID: 25316611
[TBL] [Abstract][Full Text] [Related]
2. ABI 007.
Drugs R D; 2004; 5(3):155-9. PubMed ID: 15139776
[TBL] [Abstract][Full Text] [Related]
3. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
4. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.
Yuan H; Guo H; Luan X; He M; Li F; Burnett J; Truchan N; Sun D
Mol Pharm; 2020 Jul; 17(7):2275-2286. PubMed ID: 32485107
[TBL] [Abstract][Full Text] [Related]
5. [Study of bioequiavailability of paclitaxel for Injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer].
Bian L; Geng CZ; Ouyang QC; Hu XC; Peng YY; Xiao JY; Wang MX; Yang N; Yuan J; Wang YM; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1236-1241. PubMed ID: 29747311
[No Abstract] [Full Text] [Related]
6. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; King J; Kaura S; Zhang A
Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
[TBL] [Abstract][Full Text] [Related]
7. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
9. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
11. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
Fader AN; Rose PG
Int J Gynecol Cancer; 2009 Oct; 19(7):1281-3. PubMed ID: 19820391
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.
Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA
Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Ciruelos E; Jackisch C
Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
[TBL] [Abstract][Full Text] [Related]
14. Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
Med Lett Drugs Ther; 2005 May; 47(1208):39-40. PubMed ID: 15880087
[TBL] [Abstract][Full Text] [Related]
15. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
Rahman HT; Yeh S; Bergstrom CS
J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
[TBL] [Abstract][Full Text] [Related]
16. Taxol: initial Israeli experience with a novel anticancer agent.
Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
[TBL] [Abstract][Full Text] [Related]
17. [Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer].
Tauchi Y; Kashiwagi S; Ishihara S; Asano Y; Sakimura C; Kurata K; Tokumoto M; Morisaki T; Noda S; Kawajiri H; Takashima T; Onoda N; Hirakawa K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1948-50. PubMed ID: 25731385
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Montero AJ; Adams B; Diaz-Montero CM; Glück S
Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane.
Zhao M; Li H; Bu X; Lei C; Fang Q; Hu Z
ACS Nano; 2015 Oct; 9(10):10099-112. PubMed ID: 26324059
[TBL] [Abstract][Full Text] [Related]
20. Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.
Ilinskaya AN; Clogston JD; McNeil SE; Dobrovolskaia MA
Nanomedicine; 2015 Nov; 11(8):1925-38. PubMed ID: 26282378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
